
About Azitra
Azitra is a publicly listed company based in Farmington (United States) founded in 2014. Microbiome-based therapeutics for skin conditions like eczema are developed. Azitra has raised $37.4 million across 11 funding rounds from investors including HHS, Connecticut Innovations and Bios Partners. The company has 12 employees. Its chief executive, as recorded, is Francisco Salva. Azitra offers products and services including ATR-12, ATR-04, and ATR-01. Its focus areas include Life Sciences, Genomics, Applied Genomics and Consumer Genomics. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Azitra was founded in 2014 and is headquartered in Farmington, United States, within the biotechnology sector. Focus is placed on microbiome-derived solutions for dermatological disorders, including atopic dermatitis and eczema. The lead candidate, AZT-04, addresses rashes associated with cancer therapies, while preclinical programs encompass AZT-01 for filaggrin delivery in eczema treatment and ATR-12, featuring engineered Staphylococcus epidermidis for LEKTI expression in Netherton syndrome. Operations remain centered on therapeutic development.
- Headquarters Farmington, United States
- Employees 12
- Stage Public
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website azitrainc.com
- Social LinkedIn X
- Legal Name Azitra Inc
- Net Profit-$10.96 M (USD)-22.17as on Dec 31, 2025
- EBITDA-$10.51 M (USD)-4.15as on Dec 31, 2025
- Total Equity Funding$37.4M (USD)
in 11 rounds
- Latest Funding Round$1M (USD), Series B
Jan 2021
- InvestorsHHS
& 6 more
- Employee Count12
Products & Services of Azitra
Azitra offers a comprehensive portfolio of products and services, including ATR-12, ATR-04, and ATR-01.
Engineered microbe for treating Netherton syndrome via microbial delivery.
Auxotrophic microbe to manage EGFR inhibitor-associated rashes effectively.
Filaggrin protein for addressing ichthyosis vulgaris symptoms.
Funding Insights of Azitra
Azitra has successfully raised a total of $37.4M across 11 strategic funding rounds. The most recent funding activity was a Series B round of $1 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $37.4M
- Total Rounds 11
- Last Round Series B β $1M
- First Round $150,000
(Aug 2016)
- Investors Count 7
Latest 10 of 11 funding rounds of Azitra with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2021 | $1M | Series B | β | β | β |
| Sep 2020 | $17M | Series B | β | Leaps by Bayer | |
| Oct 2019 | $14M | Series A | β | Bios Partners, KdT Ventures | |
| Apr 2019 | $719,727 | Grant | β | β | |
| Sep 2018 | Grant | β | β | ||
| Aug 2018 | $225,000 | Grant | β | β | |
| May 2018 | $2.15M | Series A | β | Connecticut Innovations | |
| Mar 2017 | $2.9M | Series A | β | Bios Partners | β |
| Jan 2017 | $225,000 | Grant | β | β | |
| Oct 2016 | $350,000 | Seed | β | Breakout Labs | β |
7 investors in total: 7 institutional.
Investors in Azitra
Azitra has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Connecticut Innovations and Bios Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital services for biotech, IT, and innovative sectors in Connecticut. | ctinnovations.com | |||
Venture capital is provided by Bios Partners for biotech innovation. | 2017 | biospartners.com | Fort Worth, United States | |
Venture capital firm investing in life sciences sector | leaps.bayer.com | Leverkusen, Germany | ||
Early-stage investments are made in frontier science ventures. | kdtvc.com | Black Mountain, United States | ||
Early-stage science-driven companies are supported through venture capital investments. | breakoutlabs.org | |||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Military forces are provided by the U.S. Department of Defense for national security. | defense.gov | Washington, D.C., United States |
Investor details for Azitra
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Azitra
11 people are tracked at Azitra (6 in leadership, 5 in board & advisors); the tracked headcount is 12.
| Name | Role | Group |
|---|---|---|
Francisco Salva | CEO | Leadership |
Travis Whitfill | Co-founder & Executive Director of Advanced Technology | Leadership |
Dorival Martins | Associate Director | Leadership |
Edward B. Punzalan | Director of GMP Manufacturing and Process Development | Leadership |
Roger Leger | VP of Chemistry, Formulation & Development | Leadership |
Peter F. | Director Of Facilities And Operations | Leadership |
Julia Oh | Advisory Board | Board & advisors |
Jeffrey L. Bose | Advisory Board | Board & advisors |
Leonard Milstone | Advisory Board | Board & advisors |
Stella M. Roberston | Director | Board & advisors |
Cain McClary | Director | Board & advisors |
Complete people profiles for Azitra
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Azitra
Azitra is a publicly listed company on the AMEX with ticker symbol AZTR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date16 Jun 2023
- Listed onNYSEAMERICAN: AZTR
- Listed entityAzitra Inc
- Exchange sectorHealth technology
- ISINUS05479L3024
- Share price$0.07 (-39.2% on the day) · 2026-10-13
- Market capitalisation$4.3M
- EPS (diluted, trailing year)$-1.31
- Volume (last session)2,670,553
Financials of Azitra
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$11.0M | -$10.5M | |
| 2024 | $7,500 | -$9.0M | -$10.1M |
| 2023 | $686,000 | -$11.3M | -$6.8M |
| 2022 | $284,000 | -$10.7M | -$9.1M |
| 2021 | $110,000 | -$8.9M | -$9.1M |
Detailed financial statements for Azitra
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Azitra
4 dated milestones of Azitra across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Azitra is founded.
- Funding First funding round of $150K.
- Funding Latest funding round, Series B, of $1.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Azitra
Azitra has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Azitra
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Azitra
The website of Azitra (azitrainc.com) receives about 5.8K visits a month.
- Monthly visits5.8K
▲ 98.9% vs previous month
Websites whose visitors overlap most with Azitra. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
franklintransit.org | franklintransit.org | 100% | #7,037,034 | β | |
azitra.com | azitra.com | 87% | #2,668,023 | β | |
azitra.us | azitra.us | 76% | β |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Azitra (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Azitra
Complete news archive for Azitra
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Azitra
Azitra was founded in 2014 and raised its 1st funding round 2 years after it was founded.
Azitra is headquartered in Farmington, United States.
Francisco Salva is the CEO of Azitra, as recorded in our data.
Azitra is a funded company, having raised a total of $37.4M across 11 funding rounds to date. The company's 1st funding round was a Seed of $350K, raised on Aug 2016.
Azitra has 12 employees.
Azitra was founded in 2014 and is headquartered in Farmington, United States, within the biotechnology sector. Focus is placed on microbiome-derived solutions for dermatological disorders, including atopic dermatitis and eczema. The lead candidate, AZT-04, addresses rashes associated with cancer therapies, while preclinical programs encompass AZT-01 for filaggrin delivery in eczema treatment and ATR-12, featuring engineered Staphylococcus epidermidis for LEKTI expression in Netherton syndrome. Operations remain centered on therapeutic development.
Azitra offers ATR-12, ATR-04, and ATR-01.
Yes, Azitra is publicly traded on AMEX under the ticker symbol AZTR.
Azitra has 7 investors. Key investors include HHS, Connecticut Innovations, Bios Partners, Leaps by Bayer, and KdT Ventures.
